Company news

BioVie Inc. news in 2024

BioVie Inc.'s news releases, calls and decks from 2024, newest first.

View company

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

November 19, 2024

BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded

November 3, 2024

BioVie Inc. Announces Closing of Registered Direct Offering

October 28, 2024

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

October 27, 2024

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

October 23, 2024

Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024

October 22, 2024

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

October 22, 2024

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

October 14, 2024

BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin

September 30, 2024

BioVie Inc. Announces Closing of Public Offering

September 24, 2024

BioVie Inc. Announces Proposed Public Offering

September 22, 2024

BioVie Inc. Announces Pricing of Public Offering

September 22, 2024

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

September 15, 2024

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

September 2, 2024

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

August 26, 2024

BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting

August 12, 2024

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease

August 7, 2024

BioVie Inc. Announces Reverse Stock Split

August 5, 2024

BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024

June 24, 2024

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress

June 19, 2024

Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26

June 11, 2024

BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

June 3, 2024

BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients

May 21, 2024

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

April 28, 2024

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints

April 24, 2024

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

April 17, 2024

BioVie Announces Pipeline Update and Near-Term Clinical Priorities

March 10, 2024

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzh...

February 29, 2024

BioVie Inc. Announces Proposed Public Offering of Common Stoc

February 29, 2024

BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 5, 2024

Decks in 2024